Epiomic Epidemiology Series: Onychomycosis Forecast in 10 Major Markets 2015-2025

August 2015 | 44 pages | ID: E205C0FDF44EN
Black Swan Analysis limited

Abstracts

Onychomycosis is a fungal infection of the nail which occurs in the hands or feet. The more notable causative agents include the fungal pathogens Trichophyton rubrum and Trichophyton mentagrophytes. This report provides the current prevalent population for Onychomycosis across 10 Major Markets (USA, France, Germany, Italy, Spain, UK, Poland, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors and prevention, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Onychomycosis have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Onychomycosis include:

• Tinea pedis infections
• Diabetes
• Peripheral vascular disease
• HIV/AIDS
• Hypercholesterolaemia
• Osteoarticular disease
• Psoriasis

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global Onychomycosis’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Onychomycosis and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Useful in the identification and trend of the prevalence numbers for the different causative agents of Onychomycosis.
• Provide a level of understanding on the impact from specific co-morbid conditions on Onychomycosis’s prevalent population.
• Identify sub-populations within Onychomycosis which require treatment.
• Gain an understanding of the specific markets that have the largest number of Onychomycosis patients.

Contents

Overview
Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis &Clinical Course
Key Co-morbid Conditions/Features Associated with the Disease
Methodology for Quantification of Patient Numbers
Top-Line Prevalence for Onychomycosis
Main Causative Agent
Average Duration of Disease
Significant Co-morbidities of Disease
Main Signs of Infection
References
Appendix

List Of Tables

LIST OF TABLES & FIGURES

Prevalence of clinically diagnosed onychomycosis, total (000s)
Prevalence of clinically diagnosed onychomycosis, males (000s)
Prevalence of clinically diagnosed onychomycosis, females (000s)
Clinically diagnosed onychomycosis by type at presentation, total (000s)
Clinically diagnosed onychomycosis by site of infection, total (000s)
Clinically diagnosed onychomycosis by main type of fungal pathogen, total (000s)
Clinically diagnosed onychomycosis by average duration of disease, total (000s)
Clinically diagnosed onychomycosis patients with diabetes, total (000s)
Clinically diagnosed onychomycosis patients with tinea pedis, total (000s)
Clinically diagnosed onychomycosis patients with hyperkeratosis, total (000s)
Clinically diagnosed onychomycosis patients with onycholysis, total (000s)
Clinically diagnosed onychomycosis patients with paronychia, total (000s)
USA Prevalence of onychomycosis by 5-yr age cohort, males (000s)
USA Prevalence of onychomycosis by 5-yr age cohort, females (000s)
France Prevalence of onychomycosis by 5-yr age cohort, males (000s)
France Prevalence of onychomycosis by 5-yr age cohort, females (000s)
Germany Prevalence of onychomycosis by 5-yr age cohort, males (000s)
Germany Prevalence of onychomycosis by 5-yr age cohort, females (000s)
Italy Prevalence of onychomycosis by 5-yr age cohort, males (000s)
Italy Prevalence of onychomycosis by 5-yr age cohort, females (000s)
Spain Prevalence of onychomycosis by 5-yr age cohort, males (000s)
Spain Prevalence of onychomycosis by 5-yr age cohort, females (000s)
United Kingdom Prevalence of onychomycosis by 5-yr age cohort, males (000s)
United Kingdom Prevalence of onychomycosis by 5-yr age cohort, females (000s)
Poland Prevalence of onychomycosis by 5-yr age cohort, males (000s)
Poland Prevalence of onychomycosis by 5-yr age cohort, females (000s)
Brazil Prevalence of onychomycosis by 5-yr age cohort, males (000s)
Brazil Prevalence of onychomycosis by 5-yr age cohort, females (000s)
Japan Prevalence of onychomycosis by 5-yr age cohort, males (000s)
Japan Prevalence of onychomycosis by 5-yr age cohort, females (000s)
India Prevalence of onychomycosis by 5-yr age cohort, males (000s)
India Prevalence of onychomycosis by 5-yr age cohort, females (000s)